Commonwealth Pain Specialists offers treatment with CTT's Calmare Pain Therapy device

Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that Commonwealth Pain Specialists, the premier pain management center in Richmond and Central Virginia, is treating patients suffering from chronic, intense neuropathic pain using CTT's Calmare® Pain Therapy medical device.

"We are excited to have John Barsanti, M.D. and Stephen Long, M.D., and their team treating patients with our Calmare device," said John B. Nano, CTT's Chairman, President and CEO. "We are all committed to improving patients' quality of life. From the growing body of evidence-based patient outcomes, we know that our Calmare device successfully treats chronic neuropathic and oncologic pain resulting from cancer, phantom limb syndrome, failed back surgery, sciatica, spinal stenosis, shingles and other maladies." 

"We are pleased to offer this non-invasive solution for our patients who suffer from severe and intractable pain," said Dr. John Barsanti. "We are already seeing the benefit to patients from using the Calmare Pain Therapy and are excited at the prospect of helping our patients avoid the negative side effects of narcotic painkillers and improve the quality of their lives."

The non-invasive Calmare Pain Therapy device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy by CTT's client, Professor Giuseppe Marineo. CTT's partner, GEOMC Co. Ltd. of Seoul, Korea is manufacturing the Calmare device, which has U.S. FDA clearance and European Union CE Mark clearance for sales. 

Source:

 Competitive Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Myocarditis risks linked to COVID-19 vaccination explained